Table 1.

miRs that regulate RAS-ERK pathway activity in a variety of cancer contexts

miR	Target(s)	Disease contexts	References
let-7	HRAS, NRAS, KRAS, cMYC	Multiple cancer contexts including lung adenocarcinoma	[Johnson et al., 2005] [Johnson et al., 2007] [Yu et al., 2007] [Kasinski and Slack, 2010] [He et al., 2010]
miR-21	RASA1, SPRED1, SPRY1, SPRY2, PTEN, PDCD4	Multiple cancer contexts including TNBCs	[Iorio et al., 2005] [Volinia et al., 2006] [Frankel et al., 2008] [Jin et al., 2013] [Mei et al., 2013] [Wickramasinghe et al., 2009] [Asangani et al., 2008] [Meng et al., 2006] [Sharma et al., 2014]
miR-206	RASA1, SPRED1, PDCD4	TNBCs	[Sharma et al., 2014] [Lin et al., 2015]
miR-31	RASA1	Colorectal carcinoma	[Sun et al., 2013]
miR-143	NRAS	Glioma	[Wang et al., 2014]
miR-514a	NF1	Melanoma	[Stark et al., 2015a]
miR-223	RASA1	Colorectal adenocarcinoma	[Sun et al., 2015]
miR-181a	KRAS	Oral squamous cell carcinoma	[Shin et al., 2011]
miR-524-5p	BRAF, ERK2	Melanoma	[Liu et al., 2014]
miR-96	KRAS	Pancreatic adenocarcinoma	[Yu et al., 2010]
miR-30c	KRAS	Breast cancer	[Tanic et al., 2012]